Impact of Consensus Guidelines, Clinical Trials, and COVID-19 on Fractionation Practices for Node-negative Intact Breast Cancer
HF-RT in node-negative intact breast cancer increased after 2015, coinciding with US and European guideline updates. Five-fraction RT increased after 2019, coinciding with COVID-19 and FAST-Forward trial results.
Authors
- George M. Cannon (ORCID: https://orcid.org/0000-0001-9724-8341)
- Matthew M. Poppe (ORCID: https://orcid.org/0000-0002-9573-1329)
- Jaden D. Evans
- Dustin Boothe
- Jessica Stauber (ORCID: https://orcid.org/0000-0003-0588-2834)
- David K. Gaffney (ORCID: https://orcid.org/0000-0002-5752-1611)
- Jonathan Grant (ORCID: https://orcid.org/0000-0002-1646-3486)
- Lindsay Burt (ORCID: https://orcid.org/0000-0002-2040-2416)
- Vilija N. Avizonis
Institutions
- Intermountain Healthcare (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- McKay Dee Hospital (US)
- Intermountain Medical Center (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1097/coc.0000000000001167
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00